Orgenesis subsidiary sells five OMPULs to Germfree for $8.34M, enters 10-year collaboration

Orgenesis Inc.

Orgenesis Maryland sells five Octomera Mobile Processing Units & Labs (OMPULs) to Germfree for $8.34M.
Germfree gets a worldwide royalty-free license to Orgenesis' Quality Management Systems Framework (OQMSF).
Germfree will exclusively manufacture and distribute OMPULs for Orgenesis worldwide for 10 years.
Each party pays the other a 15% commission on Net Sales of OMPULs/services when customer is introduced.
Strategic Collaboration Committee with 3 members from each party to oversee joint marketing and sales pipeline.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Orgenesis Inc. entered into Asset Purchase and Strategic Collaboration Agreement with Griffin Fund 3 BIDCO, Inc., ("Germfree") valued at aggregate purchase price of $8,340,000 (effective 2024-04-05).

Action: entry
Agreement: asset purchase
Counterparty: Griffin Fund 3 BIDCO, Inc., ("Germfree")
Value: aggregate purchase price of $8,340,000
Effective: 2024-04-05

Exact text from the filing

On April 5, 2024, Orgenesis Maryland LLC (“Orgenesis Maryland”), a wholly-owned subsidiary of Orgenesis Inc., entered into an Asset Purchase and Strategic Collaboration Agreement (the “Purchase Agreement”) with Griffin Fund 3 BIDCO, Inc., (“Germfree"), for the sale by Orgenesis Maryland of five Octomera Mobile Processing Units and Labs (“OMPULs”) to Germfree

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001493152-24-014329

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.